Trial Profile
Effectiveness of dalbavancin(DBV) for treatment of endocarditis and bloodstream infections(BSI) produced by gram-positive cocci
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2018
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Endocarditis; Gram-positive infections
- Focus Therapeutic Use
- 03 May 2018 New trial record
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases